
Clinicians' Guides to Radionuclide Hybrid Imaging

PET/CT

Series editors

Jamshed B. Bomanji
London, UK

Gopinath Gnanasegaran
London, UK

Stefano Fanti
Bologna, Italy

Homer A. Macapinlac
Houston, Texas, USA

More information about this series at <http://www.springer.com/series/13803>

Sue Chua
Editor

PET/CT in Radiotherapy Planning

 Springer

 **BNMS**
BRITISH NUCLEAR MEDICINE SOCIETY

Editor
Sue Chua
Department of Nuclear Medicine and PET
Royal Marsden NHS Foundation Trust
Sutton
Surrey
United Kingdom

ISSN 2367-2439 ISSN 2367-2447 (electronic)
Clinicians' Guides to Radionuclide Hybrid Imaging - PET/CT
ISBN 978-3-319-54743-5 ISBN 978-3-319-54744-2 (eBook)
DOI 10.1007/978-3-319-54744-2

Library of Congress Control Number: 2017942962

© Springer International Publishing Switzerland 2017

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Springer imprint is published by Springer Nature
The registered company is Springer International Publishing AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

*PET/CT series is dedicated to Prof Ignac
Fogelman, Dr Muriel Buxton-Thomas and
Prof Ajit K Padhy*

Foreword

Clear and concise clinical indications for PET/CT in the management of the oncology patient are presented in this series of 15 separate booklets.

The impact on better staging, tailored management and specific treatment of the patient with cancer has been achieved with the advent of this multimodality imaging technology. Early and accurate diagnosis will always pay, and clear information can be gathered with PET/CT on treatment responses. Prognostic information is gathered and can further guide additional therapeutic options.

It is a fortunate coincidence that PET/CT was able to derive great benefit from radionuclide-labelled probes, which deliver good and often excellent target to non-target signals. Whilst labelled glucose remains the cornerstone for the clinical benefit achieved, a number of recent probes are definitely adding benefit. PET/CT is hence an evolving technology, extending its applications and indications. Significant advances in the instrumentation and data processing available have also contributed to this technology, which delivers high throughput and a wealth of data, with good patient tolerance and indeed patient and public acceptance. As an example, the role of PET/CT in the evaluation of cardiac disease is also covered, with emphasis on labelled rubidium and labelled glucose studies.

The novel probes of labelled choline; labelled peptides, such as DOTATATE; and, most recently, labelled PSMA (prostate-specific membrane antigen) have gained rapid clinical utility and acceptance, as significant PET/CT tools for the management of neuroendocrine disease and prostate cancer patients, notwithstanding all the advances achieved with other imaging modalities, such as MRI. Hence, a chapter reviewing novel PET tracers forms part of this series.

The oncological community has recognised the value of PET/CT and has delivered advanced diagnostic criteria for some of the most important indications for PET/CT. This includes the recent Deauville criteria for the classification of PET/CT patients with lymphoma—similar criteria are expected to develop for other malignancies, such as head and neck cancer, melanoma and pelvic malignancies. For completion, a separate section covers the role of PET/CT in radiotherapy planning, discussing the indications for planning biological tumour volumes in relevant cancers.

These booklets offer simple, rapid and concise guidelines on the utility of PET/CT in a range of oncological indications. They also deliver a rapid aide-memoire on the merits and appropriate indications for PET/CT in oncology.

London, UK

Peter J. Ell, FMedSci, DR HC, AQA

Preface

Hybrid imaging with PET/CT and SPECT/CT combines the best of function and structure to provide accurate localisation, characterisation and diagnosis. There are extensive literature and evidence to support PET/CT, which have made significant impact in oncological imaging and management of patients with cancer. The evidence in favour of SPECT/CT especially in orthopaedic indications is evolving and increasing.

The *Clinicians' Guide to Radionuclide Hybrid Imaging* pocketbook series is specifically aimed at our referring clinicians, nuclear medicine/radiology doctors, radiographers/technologists and nurses who are routinely working in nuclear medicine and participate in multidisciplinary meetings. This series is the joint work of many friends and professionals from different nations who share a common dream and vision towards promoting and supporting nuclear medicine as a useful and important imaging speciality.

We want to thank all those people who have contributed to this work as advisors, authors and reviewers, without whom the book would not have been possible. We want to thank our members from the BNMS (British Nuclear Medicine Society, UK) for their encouragement and support, and we are extremely grateful to Dr Brian Nielly, Charlotte Weston, the BNMS Education Committee and the BNMS council members for their enthusiasm and trust.

Finally, we wish to extend particular gratitude to the industry for their continuous supports towards education and training.

London, UK

Jamshed Bomanji
Gopinath Gnanasegaran

Acknowledgements

The series coordinators and editors would like to express their sincere gratitude to the members of the British Nuclear Medicine Society, patients, teachers, colleagues, students, industry and BNMS Education Committee members, for their continued support and inspiration:

Andy Bradley
Brent Drake
Francis Sundram
James Ballinger
Parthiban Arumugam
Rizwan Syed
Sai Han
Vineet Prakash

Contents

Part I Radiotherapy Planning in Oncology: Science and Practice

- 1 Introduction** 3
Lucy Fowkes and Kate Newbold

Part II PET/CT in Radiotherapy Planning - Technical and Practical Aspects

- 2 Instrumentation** 13
Alex Dunlop
- 3 Patient Preparation** 17
Clare Ockwell and Shirley Summers
- 4 Data Acquisition, Reconstruction and Transfer** 23
David Towey and Laurence Hill
- 5 Sources of Artefacts: Consequences and Solutions** 29
Alison Tree and Maria Hawkins
- 6 Advantages and Limitations** 33
Shaista Hafeez and Robert Huddart
- 7 4D PET/CT Respiratory Gated Acquisition Techniques** 39
Iain Murray

Part III PET/CT in Radiotherapy Planning - Current Evidence and Applications

- 8 Lung Cancer** 45
Angus O'Connor and Helen M. Betts
- 9 Head and Neck Cancers** 51
Liam Welsh and Kate Newbold
- 10 GI Malignancy** 57
Irene Chong and Diana Tait

11 Prostate Cancer	63
Daniel R. Henderson and Nicholas van As	
12 Gynaecological Cancers	67
Susan Lalondrelle	
13 Paediatric Tumours	73
Lucy Fowkes and Sue Chua	
Index	77

Contributors

Nicholas van As The Royal Marsden NHS Foundation Trust, London, UK

Helen M. Betts Department of Medical Physics and Clinical Engineering, Nottingham University Hospitals NHS Trust, Nottingham, UK

Irene Chong The Royal Marsden NHS Foundation Trust, London, UK

Sue Chua Department of Nuclear Medicine and PET, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK

Alex Dunlop Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK

Lucy Fowkes The Royal Marsden NHS Foundation Trust, London, UK

Shaista Hafeez The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK

The Royal Marsden NHS Foundation Trust, London, UK

Maria Hawkins CRUK MRC Oxford Institute for Radiation Oncology, Gray Laboratories, University of Oxford, Oxford, UK

Daniel R. Henderson The Royal Marsden NHS Foundation Trust, London, UK

Laurence Hill Radiological Sciences Unit, Imperial College Healthcare NHS Trust, London, UK

Robert Huddart The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, London, UK

Susan Lalondrelle The Royal Marsden NHS Foundation Trust, London, UK

Iain Murray The Royal Marsden NHS Foundation Trust, London, UK

Kate Newbold The Royal Marsden NHS Foundation Trust, London, UK

Angus O'Connor Department of Radiology, Nottingham University Hospitals NHS Trust, Hucknall Road, Nottingham, UK

Clara Ockwell Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK

Shirley Summers Nuclear Medicine and PET Department, The Royal Marsden NHS Foundation Trust, London, UK

Diana Tait The Royal Marsden NHS Foundation Trust, London, UK

David Towey Radiological Sciences Unit, Imperial College Healthcare NHS Trust, London, UK

Alison Tree Royal Marsden NHS Foundation Trust, London, UK

Liam Welsh The Royal Marsden NHS Foundation Trust, London, UK